Executive Summary
PASCAL's one-year data in functional MR lands with a message the field has been waiting for: the MiCLASP postmarket cohort (N=295) shows atrial and ventricular FMR patients achieve comparable procedural success (96-97%), MR reduction to ≤1+ in 81-93%, and Kaplan-Meier freedom from death/HF hospitalization of 79.3% and 70.9% respectively at 12 months — tightening PASCAL's position as a legitimate alternative to MitraClip across the FMR spectrum, including the newly ESC-defined atrial phenotype. Redo-TAVR with self-expanding Evolut valves in 400+ TVT Registry patients matched native TAVR for 30-day and 1-year mortality and stroke, though residual gradients ran higher. Machine-learning models for post-TAVR pacemaker prediction remain inconsistent (AUC 0.61-0.92 across 7 studies) — not ready for the cath lab wall.
- PASCAL delivered ≥2-grade MR reduction in 93.1% of AFMR and 81.3% of VFMR patients at one year, with NYHA I/II reached by 76.5% and 64.6% (MiCLASP, Circ Cardiovasc Interv).
- Redo-TAVR in the STS/ACC TVT Registry (mean STS 9.6, 63% women) showed comparable mortality/stroke to native TAVR but persistently elevated gradients — Medtronic-funded, 1-year follow-up ceiling (JACC: Cardiovascular Interventions).
- Seven ML models trained on 4,528 TAVR patients flagged self-expanding valves, pre-existing RBBB, and LVOT calcification as top pacemaker predictors — PPM rates ranged 14-41.7% (Cardiology in Review).
- A Texas cardiologist was disciplined for allegedly leaving a guidewire in a patient — as transcatheter procedural volume expands, retained-foreign-body events remain a durable liability tail (Cardiovascular Business).
- A valve-in-valve TAVR case rescuing early Trilogy valve aortic insufficiency with Sapien S3 previews the reintervention problem for the dedicated-AR device class (Case Reports in Cardiology).
What to watch: Medtronic reports fiscal Q1 on September 1 — Evolut FX+ uptake and structural heart guidance carry the redo-TAVR narrative into investor territory.
Aortic Valve (TAVR/TAVI)
Redo-TAVR with supra-annular self-expanding valves earns a green light from registry data — with an asterisk. The JACC: Cardiovascular Interventions analysis of 400+ STS/ACC TVT Registry patients receiving Evolut R/PRO/PRO+ for failed prior TAVR showed 30-day and 1-year mortality and stroke rates comparable to native TAVR after covariate adjustment, with sustained functional and QoL gains. Residual transvalvular gradients ran higher than native TAVR, follow-up caps at one year, and the analysis is Medtronic-funded with no surgical comparator arm. The critical unanswered question — TAV-in-TAV versus surgical explant in younger, low-risk patients — is explicitly deferred by the authors: "randomized trials comparing redo TAVR and surgical explantation are needed in younger low-risk patients." Surgical explant of a failed THV carries 12-17% 30-day mortality in contemporary series, but that denominator is patients selected for explant, not an unselected redo-TAVR-eligible population. The ESC 2025 lifetime-management framework demands anatomical planning for future reintervention at the index procedure — commissural alignment, neo-skirt height, sinus sequestration risk. This registry confirms redo-TAVR is feasible when already committed to the transcatheter pathway; it does not settle lifetime strategy for patients implanted before age 70.
A scoping review of 7 machine-learning models across 4,528 TAVR patients found AUCs spanning 0.61 to 0.92 for pacemaker prediction — a range too wide for bedside application. PPM rates in the pooled cohort ran 14-41.7%. Consistent predictors: self-expanding platform, pre-existing RBBB, leaflet calcification, larger LVOT diameter. These variables are what experienced operators already weigh; the models add no incremental decision support without external validation or prospective deployment. A companion review in Acta Cardiologica frames the same challenge more broadly — integrated clinical and biomechanical prediction of TAVR complications remains aspirational.
A single case report describes [NOTABLE] valve-in-valve TAVR with Sapien S3 Ultra Resilia rescuing early Trilogy valve failure for recurrent AI. The Trilogy (JenaValve) is still in trials as the first dedicated transcatheter therapy for pure AR. If the dedicated-AR device fails early, the reintervention pathway is uncharted. ACC/AHA 2020 does not endorse TAVI for native AR; ESC 2025 rates it Class IIb only for inoperable patients with suitable anatomy. SAVR remains the reference for AR in any patient with reasonable surgical risk.
Mitral Valve (MitraClip, PASCAL, TMVR)
PASCAL now has legitimate one-year FMR data across both ventricular and atrial phenotypes, and the story holds. MiCLASP (N=295 of first 600 enrolled, multicenter European postmarket) reported procedural success of 96.2% in AFMR and 97.1% in VFMR. MR ≤1+ at one year: 93.1% AFMR, 81.3% VFMR. Mean transmitral gradients stayed low (3.5 and 3.1 mmHg). LV end-diastolic and LA volumes both contracted meaningfully. Kaplan-Meier freedom from all-cause death or HF hospitalization: 79.3% AFMR vs 70.9% VFMR (P=0.267). KCCQ jumped 18.0 points in AFMR, 11.6 in VFMR. The AFMR cohort was older (79.7 vs 74.6 years), 75% female, and predominantly hypertensive with AF — precisely the ESC 2025 atrial SMR phenotype. This is postmarket, non-randomized, and industry-relevant, but it lands PASCAL squarely in COAPT-eligible territory for VFMR and provides the first sizable AFMR outcome dataset for the platform. The AFMR cohort's lower NT-proBNP and less severe baseline MR relative to the VFMR group flatter the outcome numbers.
ESC 2025 elevated TEER for ventricular SMR to Class I LOE A on the strength of COAPT 5-year data and RESHAPE-HF2; ACC/AHA 2020 still holds it at Class IIa. For AFMR specifically, ESC 2025 recommends MV surgery plus surgical AF ablation and LAAO as Class IIa when the patient is operable, with TEER reserved at Class IIb for inoperable patients — a hierarchy the MiCLASP enthusiasm around AFMR does not rearrange. MiCLASP enrolled a high-surgical-risk population; the data support TEER as the appropriate tool for that cohort, not as a replacement for surgery in operable AFMR patients.
Tricuspid Valve (TriClip, TTVR)
No dedicated tricuspid data today. ESC 2025 gave transcatheter tricuspid treatment Class IIa LOE A on the strength of TRILUMINATE Pivotal, Tri.Fr, and TRISCEND II; ACC/AHA 2020 offers no recommendation at all. The next signal worth tracking: PASCAL's edge-to-edge success in atrial FMR — a population overlapping heavily with atrial functional TR — and whether the same operators and anatomical logic translate when they pivot rightward to the tricuspid.
Surgical vs. Transcatheter Comparisons
No head-to-head trials today. For redo-TAVR, the missing comparator is surgical explant of failed THV — contemporary series place 30-day mortality at 12-17%, with selection bias the registry design cannot resolve. For PASCAL in AFMR, ESC 2025 places surgery with AF ablation and LAAO above TEER when the patient is operable; postmarket registry data cannot rearrange that hierarchy.
Device & Technology
Machine learning for TAVR pacemaker prediction — 7 studies, 4,528 patients, AUC 0.61-0.92 — is a proof-of-concept exercise, not a deployable tool. The variance is the story: half these models perform no better than clinician gestalt, and none have undergone external validation or prospective evaluation. The consistently identified predictors (prosthesis size, pre-existing RBBB, LVOT calcium, self-expanding platform) are variables experienced operators already weigh. Without standardization and prospective validation, ML here is a research artifact.
Regulatory & Policy
A Texas cardiologist was disciplined after allegedly leaving a guidewire in a patient. Individual case, but as transcatheter procedural volume expands, retained-foreign-body events remain a durable liability tail. Every structural heart program should audit its wire counts.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close $90.87, +$0.37 (+0.41%). 6-month: +5.79%. Range $76.49-$96.29.
- Market cap $52.3B. Trailing P/E 53.77, forward 26.9. Beta 0.85. 52-week $72.30-$96.29.
- Analyst consensus: Buy. Target $100.96 (range $84-$110, 26 analysts).
- Next earnings 2026-10-29. EPS est $0.74, revenue est $1.68B.
- Institutional flows continue to build — Bank of Nova Scotia, Van Hulzen Asset Management, and OMERS all initiated or added to EW positions. Stock held above $90 on Q2 growth beat. The Sapien franchise absorbs today's redo-TAVR narrative asymmetrically — Medtronic gets the clinical citation, Edwards gets the base-case AS volume.
Medtronic (MDT)
- Close $91.14, -$1.76 (-1.89%). 6-month: -4.45%. Range $72.65-$97.09.
- Market cap $116.7B. Trailing P/E 24.9, forward 14.23. Beta 0.57. 52-week $73.31-$106.33.
- Analyst consensus: Buy. Target $98.44 (range $78-$121, 25 analysts).
- Next earnings 2026-09-01 — six days out. EPS est $1.39, revenue est $9.54B.
- Today's Evolut redo-TAVR paper lands directly into the fiscal Q1 window. Structural heart commentary is now the key sell-side listen; the JACC:CI paper is registry-based and Medtronic-funded, but it materially strengthens the Evolut lifetime-management pitch.
Abbott (ABT)
- Close $116.13, -$0.54 (-0.46%). 6-month: +1.23%. Range $81.39-$117.34.
- Market cap $202.3B. Trailing P/E 37.7, forward 19.15. Beta 0.58. 52-week $81.97-$137.49.
- Analyst consensus: Buy. Target $120.20 (range $103-$135, 25 analysts).
- Next earnings 2026-10-14. EPS est $1.42, revenue est $12.99B.
- MitraClip's Class I ESC 2025 position remains the structural heart anchor, but today's PASCAL AFMR data from MiCLASP tightens the competitive picture. Abbott's TriClip franchise continues to lead the transcatheter TR category ESC blessed at Class IIa.
Boston Scientific (BSX)
- Close $49.86, +$0.85 (+1.73%). 6-month: -34.18%. Range $42.20-$76.87.
- Market cap $72.3B. Trailing P/E 20.19, forward 14.52. Beta 0.57. 52-week $42.20-$109.50.
- Analyst consensus: Buy. Target $62.69 (range $44-$94, 29 analysts).
- Next earnings 2026-10-28. EPS est $0.81, revenue est $5.26B.
- Sinking toward 52-week lows amid the medtech selloff. The -34% 6-month drawdown makes BSX today's cheapest large-cap structural heart exposure, but the ACURATE neo2 pause post-FDA panel plus the LAA franchise cadence keep the risk/reward asymmetric.
Anteris Technologies (AVR.AX)
- Close A$12.25, +$0.18 (+1.49%). 6-month: +38.11%. Range A$7.13-A$15.47.
- Market cap ~A$1.2B. Forward P/E -5.65 (pre-revenue). 52-week A$5.20-A$15.47.
- Analyst coverage thin (1 analyst, hold, target A$13). Speculative on DurAVR pivotal execution.
Market outlook: The medtech selloff dragging BSX and MDT lower stands in tension with continued institutional buying of EW at the top of its range. The bifurcation reflects a market picking winners in structural heart on evidence quality — Edwards' Sapien franchise has the deepest RCT stack; Medtronic's Evolut is winning the reintervention narrative; Abbott's TEER portfolio benefits from the ESC 2025 Class I upgrade; Boston Scientific carries the heaviest execution overhang. Today's PASCAL FMR data is a modest positive for EW competitively — the AFMR outcome specifically — but MDT's Evolut redo-TAVR paper into a September 1 earnings print is the more consequential single event this week.
Looking Ahead
Medtronic's fiscal Q1 print on September 1 will be the first test of whether today's Evolut redo-TAVR paper translates into structural heart guidance revisions. Beyond that, the PASCAL AFMR signal from MiCLASP sets up the next round of head-to-head Abbott–Edwards TEER comparisons, and the Trilogy valve-in-valve case is a shot across the bow for the dedicated-AR device class as it moves toward pivotal data.